���他鲁肽开发背景 — Quick Reference

By Editorial Desk · published 2025-12-15 · last reviewed 2026-01-30 · Info

triple agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

This page was last updated on 2026-01-30 and is reviewed periodically as new material appears.

瑞他鲁肽开发背景

与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。

瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。

Retatrutide Background and Receptor Activity

The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.

Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.

Retatrutide at a glance

Triple Receptor Agonist Background

Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.

Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.

Related pages on this site

• Smart archive
• Modular index
• Clear overview
• Lightweight collection
• Smart toolkit
• Reliable trends
• Automated summary
• Scalable archive

Retatrutide Background and Design

Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.

Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.

Molecular Identity and Receptor Targets

Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.

Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.

Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.

Peptide Identity and Receptor Targets

Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.

Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.

Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.

Further detail

Akagha began recording for the role in September 2019, and the game was released in 2020. In the 2021 video game Deathloop, Akagha voiced Julianna, one of two main characters and the main antagonist in the game. She also played Harper Omereoha in the OWN drama television series, Delilah, which started airing in 2021. Akagha voiced Shuri in the Marvel Cinematic Universe animated series What If...?, replacing Letitia Wright. She also voiced the recurring role of Flora Flamingo in the 2021 children's show, Do, Re & Mi.

Because lithium-ion batteries can have a variety of positive and negative electrode materials, the energy density and voltage vary accordingly. The open-circuit voltage is higher than in aqueous batteries (such as lead–acid, nickel–metal hydride and nickel–cadmium). Internal resistance increases with both cycling and age, although this depends strongly on the voltage and temperature the batteries are stored at. Rising internal resistance causes the voltage at the terminals to drop under load, which reduces the maximum current draw. Eventually, increasing resistance will leave the battery in a state such that it can no longer support the normal discharge currents requested of it without unacceptable voltage drop or overheating. Batteries with a lithium iron phosphate positive and graphite negative electrodes have a nominal open-circuit voltage of 3.2 V and a typical charging voltage of 3.6 V. Lithium nickel manganese cobalt (NMC) oxide positives with graphite negatives have a 3.7 V nominal voltage with a 4.2 V maximum while charging. The charging procedure is performed at constant voltage with current-limiting circuitry (i.e., charging with constant current until a voltage of 4.2 V is reached in the cell and continuing with a constant voltage applied until the current drops close to zero). Typically, the charge is terminated at 3% of the initial charge current. In the past, lithium-ion batteries could not be fast-charged and needed at least two hours to fully charge. Current-generation cells can be fully charged in 45 minutes or less.

In information technology, a backup, or data backup is a copy of computer data taken and stored elsewhere so that it may be used to restore the original after a data loss event. The verb form, referring to the process of doing so, is "back up", whereas the noun and adjective form is "backup". Backups can be used to recover data after its loss from data deletion or corruption, or to recover data from an earlier time. Backups provide a simple form of IT disaster recovery; however not all backup systems are able to reconstitute a computer system or other complex configuration such as a computer cluster, active directory server, or database server. A backup system contains at least one copy of all data considered worth saving. The data storage requirements can be large. An information repository model may be used to provide structure to this storage. There are different types of data storage devices used for copying backups of data that is already in secondary storage onto archive files. There are also different ways these devices can be arranged to provide geographic dispersion, data security, and portability. Data is selected, extracted, and manipulated for storage. The process can include methods for dealing with live data, including open files, as well as compression, encryption, and de-duplication. Additional techniques apply to enterprise client-server backup. Backup schemes may include dry runs that validate the reliability of the data being backed up. There are limitations and human factors involved in any backup scheme.

== In popular culture == In his 1954 book The Doors of Perception, Aldous Huxley mentions the discovery and alleged effects of adrenochrome, which he likens to the symptoms of mescaline intoxication, though he had never consumed it. Anthony Burgess mentions adrenochrome as "drencrom" at the beginning of his 1962 novel A Clockwork Orange. The protagonist and his friends are drinking drug-laced milk: "They had no license for selling liquor, but there was no law yet against prodding some of the new veshches which they used to put into the old moloko, so you could peet it with vellocet or synthemesc or drencrom or one or two other veshches". Hunter S. Thompson mentioned adrenochrome in his 1971 book Fear and Loathing in Las Vegas. This is the likely origin of current myths about the compound, because a character says, "There's only one source for this stuff ... the adrenaline glands from a living human body. It's no good if you get it out of a corpse." The adrenochrome scene also appears in the novel's film adaptation. In the DVD commentary, director Terry Gilliam admits that his and Thompson's portrayal is a fictional exaggeration. Gilliam says the drug is entirely fictional and seems unaware of the existence of a substance with the same name. Thompson also mentions adrenochrome in his book Fear and Loathing on the Campaign Trail '72. In the footnotes in chapter April, page 140, he says: "It was sometime after midnight in a ratty hotel room and my memory of the conversation is hazy, due to massive ingestion of booze, fatback, and forty cc's of adrenochrome."

Sources: en.wikipedia.org

Supporting material

=== Immunology === Immunoproteomics is and has been used to increase scientific understanding of both autoimmune disease pathology and progression. Using biochemical techniques, gene and ultimately protein expression can be measured with high fidelity. With this information, the biochemical pathways causing pathology in conditions such as multiple sclerosis and Crohn's disease can potentially be elucidated. Serum antibody identification in particular has proven to be very useful as a diagnostic tool for a number of diseases in modern medicine, in large part due to the relatively high stability of serum antibodies. Immunoproteomic techniques are additionally used for the isolation of antibodies. By identifying and proceeding to sequence antibodies, scientists are able to identify potential protein targets of said antibodies. In doing so, it is possible to determine the antigen(s) responsible for a particular immune response. Identification and engineering of antibodies involved in autoimmune disease pathology may offer novel techniques in disease therapy.

=== Autism === Compared to placebo, risperidone treatment reduces certain problematic behaviors in autistic children, including aggression toward others, self-injury, challenging behavior, and rapid mood changes. The evidence for its efficacy appears to be greater than that for alternative pharmacological treatments. The risk of rapid weight gain is an important consideration when prescribing it. Some authors recommend limiting the use of risperidone and aripiprazole to those with the most challenging behavioral disturbances to minimize the risk of drug-induced adverse effects. Evidence for the efficacy of risperidone in autistic adolescents and young adults is less persuasive.

== Phytochemicals == Polyphenol research on maqui berries showed anthocyanin content to include eight glucoside pigments of delphinidin and cyanidin, with the principal anthocyanin being delphinidin 3-sambubioside-5-glucoside (34% of total anthocyanins). The average total anthocyanin content was 138 milligrams (2.13 gr) per 100 grams (3.5 oz) of fresh fruit, or 212 milligrams (3.27 gr) per 100 grams (3.5 oz) of dry fruit, ranking maqui berries low among darkly pigmented fruits for anthocyanin content (see table at anthocyanins). One study found that anthocyanins are also present in maqui leaves. Other phytochemicals extracted from the leaves were the alkaloids aristoteline, aristoquinoline, and aristone.

An almost immediate move to challenge Gaddis' framework came from Melvyn P. Leffler, who "demonstrated that it was not so much the actions of the Kremlin as it was fears about socioeconomic dislocation, revolutionary nationalism, British weakness, and Eurasian vacuums of power that triggered US initiatives to mold an international system to comport with its concept of security". That provoked "strong rebuttals" from Gaddis and his followers, but Leffler deemed their objections inaccurate and unsubstantiated. However, Leffler himself still falls within the overall post-revisionist camp. Out of the "post-revisionist" literature emerged a new area of inquiry that was more sensitive to nuance and interested less in the question of who started the conflict than in offering insight into United States and Soviet actions and perspectives. From that perspective, the Cold War was not so much the responsibility of either side, but rather the result of predictable tensions between two world powers that had been suspicious of one another for nearly a century. For example, Ernest May wrote in a 1984 essay:

== In popular culture == Ricin has been used as a plot device, such as in the television series Breaking Bad. The popularity of Breaking Bad inspired several real-life criminal cases involving ricin or similar substances. Kuntal Patel from London attempted to poison her mother with abrin after the latter interfered with her marriage plans. Daniel Milzman, a 19-year-old former Georgetown University student, was charged with manufacturing ricin in his dorm room, as well as the intent of "[using] the ricin on another undergraduate student with whom he had a relationship". Mohammed Ali from Liverpool, England, was convicted after attempting to purchase 500 mg of ricin over the dark web from an undercover FBI agent. He was sentenced on 18 September 2015 to eight years imprisonment. In Agatha Christie's 1929 short story The House of Lurking Death, ricin is used as a plot device.

Sources: en.wikipedia.org

Supporting material

== Toxicity == DBNPA exhibits various degrees of toxicity like acute oral toxicity, dermal toxicity and inhalation toxicity while it is stable under normal conditions of use. Contact with strong amines should however be avoided including bases, oxidizing agents and reducing agents. DBNPA is corrosive to mild steel, iron and aluminum. The creation of dust when handling DBNPA should be avoided and precautionary measures against electrostatic discharges should be taken. Avoid heat, open flames and other potential sources of ignition when handling DBNPA. Additionally, DBNPA is corrosive to the eyes. It is moderately toxic by oral or inhalation routes and slightly toxic by the dermal route. DBNPA can kill skin tissue in rabbits when administered at high doses for a prolonged period of time. DBNPA is also a skin sensitizer. In a toxicity study using rats, DBNPA caused breathing difficulty associated with lung or heart disease, as well as weight loss and several deaths at higher doses. When applied to the skin of rats in another study, DBNPA caused changes in body chemistry and dermal irritation at the higher doses. DBNPA is a developmental toxicant in rabbits. It was shown to cause structural alterations (retarded ossification of several fetal skeleton elements) at a maternally non-toxic dose level. DBNPA is not mutagenic. The United States Environmental Protection Agency (EPA) has received several human incident reports in which eye, throat and respiratory irritation, runny nose and headache resulted from spills or misuse of DBNPA.

While arginine, glutamine and other amino acids are rapidly consumed often very early in fermentation, proline is not consumed by yeast at all during the normal, anaerobic conditions of fermentations. This is because one of the enzymes required for its use is an oxidase (requiring molecular oxygen) and the other is repressed by the presence of ammonium (another source of assimilable nitrogen needed by yeast) in the must. However, well aerated starter cultures that contain must which hasn't had any diammonium phosphate added it to it will usually see some utilization of proline before the anaerobic conditions of fermentation kick in. When winemakers measure FAN, they need to be aware if their assay is including proline since this will make their YAN measurement higher. Chardonnay and Cabernet Sauvignon are two Vitis vinifera varieties that are known to have very high proline levels while Riesling and Sauvignon blanc usually have very low levels. Yeast transport amino acids and small peptides (less than 5 amino acid residues) into the cell via an active transport process that utilizes specialized membrane proteins and the difference in the pH gradient of the acidic wine solution (pH between 3-4) and the near neutral pH of cytoplasm inside the yeast cells. The proton symport proteins in the membrane take in the amino acid coupled with a hydrogen ion that later gets expelled by the cell via a hydrogen ion pump.

== Synthesis == Albertus Magnus, in the 13th century, documented the ability of nitric acid to separate gold and silver by dissolving the silver. It was once called lunar caustic because silver was called luna by ancient alchemists who associated silver with the moon. Indeed silver nitrate can be prepared by dissolving silver in nitric acid followed by evaporation of the solution. The stoichiometry of the reaction depends upon the concentration of nitric acid.

Some hormones, such as insulin and growth hormones, can be released into the bloodstream already fully active. Other hormones, called prohormones, must be activated in certain cells through a series of steps that are usually tightly controlled. The endocrine system secretes hormones directly into the bloodstream, typically via fenestrated capillaries, whereas the exocrine system secretes its hormones indirectly using ducts. Hormones with paracrine function diffuse through the interstitial spaces to nearby target tissue. Plants lack specialized organs for the secretion of hormones, although there is a spatial distribution of hormone production. For example, the hormone auxin is produced mainly at the tips of young leaves and in the shoot apical meristem. The lack of specialised glands means that the main site of hormone production can change throughout the life of a plant, and the site of production is dependent on the plant's age and environment.

During this period, state and local governments initiated controversial drug policies that demonstrated racial biases, such as the stop-and-frisk police practice in New York City, and state-level "three strikes" felony laws, which began with California in 1994. During the 1990s, opioid use in the US dramatically rose, leading to the ongoing situation commonly called the opioid epidemic. A loose consensus of observers describe three main phases to date: overprescription of legal opioids beginning in the early to mid-1990s; a rise in heroin use in the later 2000s as prescription opioids became more difficult to obtain; and the rise of more powerful fentanyl and other synthetic opioids around the mid-2010s. Prior to 1990s, the use of opioids to treat chronic pain in the US was limited; some scholars suggest there was hesitation to prescribe opioids due to historical problems with addiction dating back to the 1800s. A critical point in the development of the epidemic is often seen as the release in 1996 of OxyContin (oxicodone) by Purdue Pharma, and the subsequent aggressive and deceptive opioid marketing efforts by Purdue and other pharma companies, conducted without sufficient official oversight. Thus the problem emerged from within the healthcare system: the DEA initially targeted doctors, pharmacists, pill mills, and pharmaceutical companies. As law enforcement cracked down on the pharmaceutical supply, illicit drug trafficking in opioids grew to meet demand. The George W. Bush (2001–2009) administration maintained the hard line approach.

Sources: en.wikipedia.org

Frequently asked questions